Thalidomide in the management of multiple myeloma

This publication has 19 references indexed in Scilit:

• Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
  Blood, 2001
• Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
  British Journal of Haematology, 2000
• Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone
  Bone Marrow Transplantation, 2000
• Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
  New England Journal of Medicine, 1999
• Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma
  British Journal of Haematology, 1996
• A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
  New England Journal of Medicine, 1996
• Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade
  Immunopharmacology, 1996
• Autologous Bone Marrow and Peripheral Blood Stem Cell Transplantation in Multiple Myeloma
  Cancer Investigation, 1996
• Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating Agents
  New England Journal of Medicine, 1984
• HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA
  The Lancet, 1983